Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 0.4% – What’s Next?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s share price shot up 0.4% on Friday . The company traded as high as $0.86 and last traded at $0.8349. 574,837 shares were traded during trading, a decline of 95% from the average session volume of 11,661,692 shares. The stock had previously closed at $0.8316.

Wall Street Analysts Forecast Growth

ENLV has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enlivex Therapeutics in a report on Monday, December 8th. Wall Street Zen raised Enlivex Therapeutics to a “sell” rating in a research report on Saturday, August 30th. D. Boral Capital reiterated a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. D Boral Capital lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Enlivex Therapeutics in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Enlivex Therapeutics Stock Performance

The stock’s 50-day simple moving average is $1.01 and its two-hundred day simple moving average is $1.10. The stock has a market cap of $20.28 million, a price-to-earnings ratio of -1.52 and a beta of 1.49.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. As a group, research analysts predict that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ENLV. Susquehanna International Group LLP bought a new stake in shares of Enlivex Therapeutics in the third quarter valued at approximately $57,000. Jane Street Group LLC grew its stake in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after acquiring an additional 67,886 shares during the last quarter. Finally, Citizens Financial Group Inc. RI bought a new position in Enlivex Therapeutics during the third quarter worth $241,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.